Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.
|Articles|April 1, 2003
Spotlight intensifies on cancer drug reimbursement
Pharmaceutical manufacturers have long been under scrutiny for the methodsthey employ in marketing their products to physicians. Now, increasing concernthat drug makers are winning physician favor by deeply discounting chemotherapymedicines is placing those physicians under the microscopes of federal andstate authorities.
Advertisement
Advertisement
Related to this article
LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
3
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5